Beauty Health Analyst Ratings
Beauty Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2023 | 240.24% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 08/25/2023 | 47.93% | Canaccord Genuity | → $10 | Assumes | → Buy |
| 08/10/2023 | 33.14% | TD Cowen | $15 → $9 | Maintains | Outperform |
| 08/10/2023 | 144.08% | DA Davidson | $35 → $16.5 | Maintains | Buy |
| 08/08/2023 | 240.24% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 06/21/2023 | 47.93% | Stifel | $17 → $10 | Downgrades | Buy → Hold |
| 05/26/2023 | 77.51% | JP Morgan | $13 → $12 | Maintains | Neutral |
| 05/18/2023 | 240.24% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 05/11/2023 | 417.75% | DA Davidson | → $35 | Reiterates | → Buy |
| 03/28/2023 | 166.27% | Canaccord Genuity | → $18 | Reiterates | → Buy |
| 03/20/2023 | — | Exane BNP Paribas | Upgrades | Underperform → Neutral | |
| 03/14/2023 | 240.24% | Benchmark | → $23 | Reiterates | → Buy |
| 03/01/2023 | 417.75% | DA Davidson | $32 → $35 | Maintains | Buy |
| 02/28/2023 | 240.24% | Benchmark | → $23 | Reiterates | → Buy |
| 02/16/2023 | 121.89% | Cowen & Co. | $20 → $15 | Maintains | Outperform |
| 11/23/2022 | 181.07% | Goldman Sachs | $22 → $19 | Maintains | Buy |
| 11/09/2022 | 62.72% | JP Morgan | $22 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2022 | 373.37% | DA Davidson | $31 → $32 | Maintains | Buy |
| 09/28/2022 | 358.58% | DA Davidson | $30 → $31 | Maintains | Buy |
| 09/16/2022 | 240.24% | Piper Sandler | $20 → $23 | Maintains | Overweight |
| 09/16/2022 | 343.79% | DA Davidson | $25 → $30 | Maintains | Buy |
| 08/16/2022 | 225.44% | Goldman Sachs | $25 → $22 | Maintains | Buy |
| 08/10/2022 | 195.86% | Piper Sandler | $22 → $20 | Maintains | Overweight |
| 08/10/2022 | 269.82% | DA Davidson | $24 → $25 | Maintains | Buy |
| 07/08/2022 | 225.44% | Piper Sandler | $24 → $22 | Maintains | Overweight |
| 06/30/2022 | 195.86% | Canaccord Genuity | $22 → $20 | Maintains | Buy |
| 05/12/2022 | 255.03% | DA Davidson | $35 → $24 | Maintains | Buy |
| 05/11/2022 | 269.82% | Goldman Sachs | $29 → $25 | Maintains | Buy |
| 05/11/2022 | 255.03% | Piper Sandler | $26 → $24 | Maintains | Overweight |
| 04/28/2022 | 284.62% | Piper Sandler | $31 → $26 | Maintains | Overweight |
| 03/14/2022 | 240.24% | Benchmark | $18 → $23 | Maintains | Buy |
| 03/11/2022 | 255.03% | JP Morgan | → $24 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 417.75% | DA Davidson | $32 → $35 | Maintains | Buy |
| 01/07/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/23/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 11/10/2021 | 373.37% | DA Davidson | $26 → $32 | Maintains | Buy |
| 10/08/2021 | 388.17% | Stifel | → $33 | Initiates Coverage On | → Buy |
| 10/04/2021 | 373.37% | Cowen & Co. | → $32 | Initiates Coverage On | → Outperform |
| 08/11/2021 | 284.62% | DA Davidson | $17.5 → $26 | Maintains | Buy |
| 07/19/2021 | 225.44% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 07/01/2021 | 358.58% | Goldman Sachs | → $31 | Initiates Coverage On | → Buy |
| 06/24/2021 | 255.03% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
| 06/15/2021 | 210.65% | Canaccord Genuity | → $21 | Initiates Coverage On | → Buy |
| 06/01/2021 | 158.88% | DA Davidson | $16 → $17.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/13/2023 | 240.24% | 基准 | →$23 | 重申 | 购买→购买 |
| 2023年08月25日 | 47.93% | 卡纳科特·格纳奇 | →$10 | 假设 | →购买 |
| 2023年08月10日 | 33.14% | TD Cowen | $15→$9 | 维护 | 跑赢大盘 |
| 2023年08月10日 | 144.08% | 达·戴维森 | $35→$16.5 | 维护 | 买 |
| 2023/08/08 | 240.24% | 基准 | →$23 | 重申 | 购买→购买 |
| 2023年6月21日 | 47.93% | Stifel | $17→$10 | 评级下调 | 购买→Hold |
| 2023年05月26日 | 77.51% | 摩根大通 | $13→$12 | 维护 | 中性 |
| 2023年05月18日 | 240.24% | 基准 | →$23 | 重申 | 购买→购买 |
| 2023年05月11日 | 417.75% | 达·戴维森 | →$35 | 重申 | →购买 |
| 03/28/2023 | 166.27% | 卡纳科特·格纳奇 | →$18 | 重申 | →购买 |
| 03/20/2023 | - | 法国巴黎银行 | 升级 | 表现不佳的→中性 | |
| 03/14/2023 | 240.24% | 基准 | →$23 | 重申 | →购买 |
| 03/01/2023 | 417.75% | 达·戴维森 | $32→$35 | 维护 | 买 |
| 02/28/2023 | 240.24% | 基准 | →$23 | 重申 | →购买 |
| 02/16/2023 | 121.89% | 考恩公司 | $20→$15 | 维护 | 跑赢大盘 |
| 2022年11月23日 | 181.07% | 高盛 | $22→$19 | 维护 | 买 |
| 11/09/2022 | 62.72% | 摩根大通 | $22→$11 | 评级下调 | 超重→中性 |
| 11/09/2022 | 373.37% | 达·戴维森 | $31→$32 | 维护 | 买 |
| 09/28/2022 | 358.58% | 达·戴维森 | $30→$31 | 维护 | 买 |
| 09/16/2022 | 240.24% | 派珀·桑德勒 | $20→$23 | 维护 | 超重 |
| 09/16/2022 | 343.79% | 达·戴维森 | $25→$30 | 维护 | 买 |
| 08/16/2022 | 225.44% | 高盛 | $25→$22 | 维护 | 买 |
| 2022年08月10日 | 195.86% | 派珀·桑德勒 | $22→$20 | 维护 | 超重 |
| 2022年08月10日 | 269.82% | 达·戴维森 | $24→$25 | 维护 | 买 |
| 07/08/2022 | 225.44% | 派珀·桑德勒 | $24→$22 | 维护 | 超重 |
| 2022/06/30 | 195.86% | 卡纳科特·格纳奇 | $22→$20 | 维护 | 买 |
| 2022年05月12日 | 255.03% | 达·戴维森 | $35→$24 | 维护 | 买 |
| 2022年05月11日 | 269.82% | 高盛 | $29→$25 | 维护 | 买 |
| 2022年05月11日 | 255.03% | 派珀·桑德勒 | $26→$24 | 维护 | 超重 |
| 04/28/2022 | 284.62% | 派珀·桑德勒 | $31→$26 | 维护 | 超重 |
| 03/14/2022 | 240.24% | 基准 | $18→$23 | 维护 | 买 |
| 03/11/2022 | 255.03% | 摩根大通 | →$24 | 开始承保 | →超重 |
| 02/23/2022 | 417.75% | 达·戴维森 | $32→$35 | 维护 | 买 |
| 01/07/2022 | - | 威廉·布莱尔 | 开始承保 | →跑赢大盘 | |
| 2021年12月23日 | - | 雷蒙德·詹姆斯 | 开始承保 | →市场表现 | |
| 2021年11月10日 | 373.37% | 达·戴维森 | $26→$32 | 维护 | 买 |
| 10/08/2021 | 388.17% | Stifel | →$33 | 开始承保 | →购买 |
| 10/04/2021 | 373.37% | 考恩公司 | →$32 | 开始承保 | →跑赢大盘 |
| 2021/08/11 | 284.62% | 达·戴维森 | $17.5→$26 | 维护 | 买 |
| 07/19/2021 | 225.44% | 杰富瑞 | →$22 | 开始承保 | →购买 |
| 07/01/2021 | 358.58% | 高盛 | →$31 | 开始承保 | →购买 |
| 06/24/2021 | 255.03% | 派珀·桑德勒 | →$24 | 开始承保 | →超重 |
| 2021/06/15 | 210.65% | 卡纳科特·格纳奇 | →$21 | 开始承保 | →购买 |
| 06/01/2021 | 158.88% | 达·戴维森 | $16→$17.5 | 维护 | 买 |
What is the target price for Beauty Health (SKIN)?
美容健康(皮肤)的目标价格是多少？
The latest price target for Beauty Health (NASDAQ: SKIN) was reported by Benchmark on September 13, 2023. The analyst firm set a price target for $23.00 expecting SKIN to rise to within 12 months (a possible 240.24% upside). 21 analyst firms have reported ratings in the last year.
美容健康(纳斯达克：皮肤)的最新目标价于2023年9月13日由Benchmark报道。这家分析公司将目标价定为2300美元，预计皮肤价格将在12个月内上涨(可能上涨240.24%)。去年有21家分析公司公布了评级。
What is the most recent analyst rating for Beauty Health (SKIN)?
美容健康(皮肤)的最新分析师评级是多少？
The latest analyst rating for Beauty Health (NASDAQ: SKIN) was provided by Benchmark, and Beauty Health reiterated their buy rating.
美容健康(纳斯达克：Skin)的最新分析师评级由Benchmark提供，美容健康重申其买入评级。
When is the next analyst rating going to be posted or updated for Beauty Health (SKIN)?
美容健康(皮肤)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beauty Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beauty Health was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Beauty Health的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。上一次对美容健康的评级是在2023年9月13日提交的，所以你应该预计下一次评级将在2024年9月13日左右公布。
Is the Analyst Rating Beauty Health (SKIN) correct?
分析师对美容健康(皮肤)的评级正确吗？
While ratings are subjective and will change, the latest Beauty Health (SKIN) rating was a reiterated with a price target of $0.00 to $23.00. The current price Beauty Health (SKIN) is trading at is $6.76, which is within the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的美容健康(皮肤)评级被重申，目标价格在0.00美元到23.00美元之间。美容健康(皮肤)目前的交易价格为6.76美元，在分析师的预测范围内。